U.S. market Closed. Opens in 17 hours 19 minutes

ACRV | Acrivon Therapeutics, Inc. Common Stock Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-31
RevenueN/AN/AN/AN/A
Cost of Revenue536.00K1.09M832.00K13.00K
Gross Profit-536.00K-1.09M-832.00K-13.00K
Operating Expenses66.70M32.66M16.18M3.17M
Selling, General & Admin21.21M8.71M2.47M1.30M
Research & Development45.49M23.95M13.72M1.87M
Other Operating ExpensesN/A1.49M-59.00K-2.14M
Operating Income-67.24M-32.66M-16.18M-3.17M
Other Expenses / Income6.85M1.49M-59.00K-2.14M
Before Tax Income-60.39M-31.17M-16.24M-5.31M
Income Tax Expenses1.00-1.49M-199.56K-193.30K
Net Income-60.39M-29.68M-16.24M-5.31M
Interest ExpensesN/A-1.49MN/AN/A
Basic Shares Outstanding22.08M21.92M20.86M20.86M
Diluted Shares Outstanding22.08M21.92M20.86M20.86M
EBITDA-66.70M-32.66M-16.15M-3.15M
EBITDA Margin0.00%0.00%0.00%0.00%
EBIT-60.39M-32.66M-16.44M-5.50M
EBIT Margin0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙